175 filings
Page 3 of 9
S-8
ethcb2ma72kggo6dy7h
9 Aug 22
Registration of securities for employees
12:00am
8-K
19j7j9sr7d33ij4i12
29 Jun 22
Departure of Directors or Certain Officers
4:30pm
8-K
ei9kd02p80
10 Jun 22
Submission of Matters to a Vote of Security Holders
4:30pm
8-K
547gr94
24 May 22
Regulation FD Disclosure
7:00am
8-K
wzp22lx
18 May 22
AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) annual meeting
8:30am
8-K
axj5 l4f6vc4nt12bf5
17 May 22
AVROBIO Reports Positive Data from Phase 1/2 Clinical Trial of Investigational
7:12am
8-K
xipijx zkf6
10 May 22
AVROBIO Reports First Quarter 2022 Financial Results and Provides Business Update
7:05am
DEFA14A
2f7we2 ha6qyrewd49
27 Apr 22
Additional proxy soliciting materials
5:03pm
S-8
49uai4g44q8qb0b aq
17 Mar 22
Registration of securities for employees
4:56pm
8-K
5z5ri8scfl
17 Mar 22
AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update
7:54am
8-K
9nn8z 2u48u
9 Feb 22
AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial
7:11am
8-K
pzy7e yl09xnhha5e1
7 Jan 22
Cost Associated with Exit or Disposal Activities
4:21pm
8-K
da7ho
4 Jan 22
Other Events
7:08am
8-K
eft ma6v0gr
4 Nov 21
AVROBIO Reports Third Quarter 2021 Financial Results and Provides Business Update
7:32am
8-K
9buqi cwdqmen7nm4p
19 Oct 21
AVROBIO Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry and Gaucher Disease Type 1
7:15am
8-K
npvi5f gh
9 Aug 21
Other Events
9:06am